---
title: "20/20 Biolabs Initiates Emergency Lab Testing Plans For Ebola And Hantavirus If Outbreak Arises"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287616991.md"
description: "20/20 Biolabs, Inc. (AIDX) is developing contingency plans for potential PCR testing of Ebola and Hantavirus in its accredited laboratory. The company is engaging with global PCR test kit developers and testing the reuse of COVID-19 PCR equipment. No regulatory approval or commercialization for these tests has been initiated. Biolabs shares closed at $0.98, down 18.67%, and are trading at $0.946 in pre-market, down 3.47%."
datetime: "2026-05-26T10:10:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287616991.md)
  - [en](https://longbridge.com/en/news/287616991.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287616991.md)
generator: "portal-rs"
---

# 20/20 Biolabs Initiates Emergency Lab Testing Plans For Ebola And Hantavirus If Outbreak Arises

(RTTNews) - 20/20 Biolabs, Inc. (AIDX), a diagnostic firm focused on laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced that it is developing contingency plans to potentially support Ebola and Hantavirus PCR testing in its College of American Pathologists (CAP)-accredited Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory, if required by public health laboratories.

Company Profile

20/20 Biolabs is an AI-powered laboratory-based blood tests for early detection and prevention of diseases and cancers.

Biolabs One Test brand offers two lab tests, one for Cancer known as the multi-cancer early detection (MCED) blood test and one for Longevity, which measures inflammatory biomarkers and is commercially available.

Earlier in the COVID-19 pandemic, the company had contracts with Montgomery County and the Maryland Department of Health through which it provided large-scale Polymerase Chain Reaction (PCR) lab testing.

Key Highlights

In response to the recent Ebola and Hantavirus outbreaks, the company has begun engaging with numerous global developers of PCR test kits to evaluate potential supply chain options.

The firm is further testing the reuse of its PCR equipment from the COVID-19 pandemic. Meanwhile, the firm stated that no regulatory authorisation, clinical availability, or commercialisation for an Ebola or Hantavirus test has been initiated.

Biolabs shares closed at $0.98 on Friday, down 18.67%. In the pre-market, shares are trading at $0.946, 3.47% down. 

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [AIDX.US](https://longbridge.com/en/quote/AIDX.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [iSpecimen ships hundreds of cancer blood specimens for international research order within three weeks](https://longbridge.com/en/news/296531044.md)
- [10:30 ETCancer Diagnostics Market worth $44.92 billion by 2031 - Exclusive Report by MarketsandMarkets™](https://longbridge.com/en/news/296121121.md)
- [Why Iovance Biotherapeutics Stock Hit 52-Week High](https://longbridge.com/en/news/296522969.md)
- [NanoViricides wins DRC ACOREP clearance for Phase II NV-387 Ebola treatment trial](https://longbridge.com/en/news/296228628.md)
- [Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test](https://longbridge.com/en/news/296382081.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**